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Interpreting the Results of Cost-Effectiveness Studies
David J. Cohen, MD, MSC, FACC,* Matthew R. Reynolds, MD, MSC, FACC†
Kansas City, Missouri; and Boston, Massachusetts
In developed nations, health care spending is an increasingly important economic and political issue. The
discipline of cost-effectiveness (CE) analysis has developed over several decades as a tool for objectively
assessing the value of new medical strategies, by simultaneously examining incremental health benefits in
light of incremental costs. The underlying goal of CE research is to allow clinicians and policymakers to
make more rational decisions regarding clinical care and resource allocation. This review will provide the
reader with an understanding of the theoretical underpinnings of CE analysis, the types of analyses com-
monly performed and reported in the medical literature, some important strengths and weaknesses of dif-
ferent analytical approaches, and key principles in the interpretation of CE results. Key principles reviewed
include the impact of analytic perspective, the importance of proper incremental comparisons, the effect of
time horizon, and methods for exploring and describing uncertainty. Illustrative examples from the cardiol-
ogy literature are discussed. (J Am Coll Cardiol 2008;52:2119–26) © 2008 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.09.018s
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weveloped nations face difficult decisions about how to allocate
esources to health care, and how to prioritize spending within
heir health care systems. In the U.S., for example, over at least
everal decades, the growth in spending on health care has
onsistently outpaced the growth of the overall economy.
hile most observers agree that this trend is unsustainable
ong term, and is already producing political and economic
roblems, enacting measures to reduce the growth in health
are spending has proved difficult (1).
It has long been recognized that new medical products
nd technologies are one important driver of increased
ealth care costs (2– 4). This realization has increasingly
ighlighted the need to assess the value of new clinical
trategies as they are introduced, that is, to measure the
enefits of tests, drugs, procedures, and medical devices
elative to their costs. The discipline of cost-effectiveness
CE) analysis aims to evaluate such questions in order to
nform medical decision making and health care policy.
undamentals of Health Economic Assessment
ealth economic studies can take many forms and report
variety of possible outcomes. Typically, 1 or more new
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ccepted September 29, 2008.trategies are compared against an existing standard of
are with regard to the dual outcomes of clinical effec-
iveness and cost. One can readily visualize the possible
esults of such joint comparisons in a 2-dimensional plot
5)— often referred to as the “cost-effectiveness plane”
Fig. 1)—in which the standard of care occupies the
rigin of the graph. The new intervention(s) under study
ill locate themselves to the right or left of the origin if
hey are more or less effective than the current standard of
are, and above or below the origin if they are more or
ess costly.
When a new intervention is both clinically superior and
ost saving, it is referred to as an economically “dominant”
trategy. The opposite is a “dominated” strategy. Few novel
echnologies will fall into either of these categories, how-
ver; the most common scenario is that a new strategy
mproves clinical results at increased cost. In these cases, the
stimation of value is based upon calculation of a CE ratio
see the following text).
These different potential outcomes give rise to a variety of
erms for individual types of health economic studies. A
tudy aimed at establishing the least costly among clinically
quivalent strategies is called a cost-minimization study, but
ost-minimization studies rely on the premise that clinical
quivalence has been proven, which can be difficult and
ometimes controversial (6). Therefore, readers should be
areful to evaluate the clinical evidence for equivalence or
herapeutic interchangeability before placing much weight
n the results of a cost-minimization study. CE studies, in
ontrast, calculate incremental costs in units of currency,
hile expressing clinical benefits in nonmonetary terms suchs life-years gained or adverse events avoided. Cost-utility
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estimate effectiveness using mea-
sures that reflect individual or
societal preferences for differing
health states, such as quality-
adjusted life years (QALYs).
As mentioned, the majority of
new health strategies improve
clinical results at increased cost.
The generic formula for calculat-
ing a CE ratio in these cases is as
follows:
CE ratio
CostNewCostReference
ENewEReference
here E is the effectiveness measure. Like any statistical
easure, the point estimate for a CE ratio obtained using
he above formula is surrounded by some degree of uncer-
ainty, and that uncertainty may overlie more than 1
uadrant of the CE plane. Specialized methods have been
eveloped to measure and display this uncertainty (see the
ollowing text).
No single threshold exists for deciding whether or not a
E ratio is acceptable. Obviously, a variety of consider-
tions including the prosperity of a nation or health system
ould dictate what type of thresholds might be affordable.
ithin the U.S., where no policy-making emanates directly
rom CE analysis (at least at present), CE ratios of
$50,000 per life year gained are generally considered attrac-
ive, and $100,000 per life year gained are generally consid-
Figure 1 The CE Plane
With some reference strategy occupying the origin of the graph, a cost-effec-
tiveness (CE) study can plot the incremental costs (y-axis) and benefits (x-axis)
of alternative strategies, relative to this reference, in 2-dimensional space. The
area above the horizontal is cost-increasing, and to the right of the vertical,
clinically beneficial. When a new strategy adds both benefits and costs (upper
right-hand quadrant) or reduces both (lower left-hand quadrant), a CE ratio
must be calculated to judge benefits relative to costs.
Abbreviations
and Acronyms
CE  cost-effectiveness
CRT-D  cardiac
resynchronization therapy
defibrillator
CRT-P  cardiac
resynchronization therapy
pacemaker
DES  drug-eluting stent(s)
iCER  incremental cost-
effectiveness ratio
QALY  quality-adjusted
life yearcred unattractive, but these are rough guidelines at best and
ave been criticized as outdated and artificially low (7,8).
In other nations such as the United Kingdom and
ustralia, however, health economic studies are an integral
omponent of the evaluation of any new medical treatment,
nd explicit CE thresholds (e.g., £30,000 per QALY
ained) have been promulgated, though not always as
bsolute standards (9). Health economic studies, therefore,
ust be interpreted within the appropriate geopolitical
ontext, and CE ratios, when published, are often compared
ith those from previous studies of other interventions that
ere accepted (or not) at clinical and policy levels. While
his type of “relativism” has flaws (e.g., many accepted
ractices have never been subjected to careful health eco-
omic scrutiny), it does provide a quantitative and objective
erspective on the value of new technologies and treatment
trategies.
Several corollaries can be discerned from the formula for
alculating the CE ratios. First, it should be self-evident
hat treatments that increase net cost compared with the
vailable alternatives can only be cost-effective if they
rovide a net clinical benefit. Second, cost-saving strategies
end to be cost-effective only if they are at least close to
linically neutral, but this depends on the CE threshold.
hus, cost-saving and -effective are not synonymous terms,
nd it is possible for a less expensive and slightly less
ffective strategy to be preferred on health economic
rounds, particularly in settings where resources are highly
onstrained (10). In contrast, even interventions that are
uite expensive may be reasonably cost-effective if they
esult in significant gains in life expectancy and the CE
hreshold is high.
easuring costs. In 1996, the U.S. Panel on Cost-
ffectiveness in Health and Medicine codified the preferred
ssignment of costs and benefits to the numerator and
enominator of CE ratios in an effort to foster methodolog-
cal consistency across studies (11). Important categories of
ost that should be measured in health economic studies
nclude the direct medical costs associated with each clinical
trategy; “induced” or downstream costs incurred (e.g., those
ssociated with late complications) or avoided (e.g., subse-
uent hospital admissions) due to the strategy; and certain
ndirect costs, such as time and travel for family members
ho often act as unpaid caregivers. Well-conducted analyses
ust fairly and accurately account for each of these costs. In
he decentralized U.S. health care system, this often requires
he careful collection and review of claims data, the fastid-
ous collection of resource utilization data (which can be
onverted to costs using representative price weights for
ach item), or both.
The U.S. panel further recommends that the economic
mpact of illness on individual patients (e.g., lost wages from
isability or death) be incorporated in the denominator of a
E ratio (as reflected in life expectancy or quality-adjusted
ife expectancy) and not in the numerator. Such productivity
osts, while sometimes important for understanding the full
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December 16/23, 2008:2119–26 Interpreting CE Studiesconomic impact of an illness, are, therefore, frequently not
ncluded in contemporary CE studies.
easuring effectiveness. There are, theoretically, few con-
traints on what measure of effectiveness is used in the
enominator of a CE ratio, although some measures clearly
ave more appeal than others. Changes in life expectancy
enerally trump other outcomes and form the focus of many
ealth economic studies in cardiology (e.g., for implantable
efibrillators or coronary revascularization). Advantages of
his approach include the unquestioned value that patients
ttach to improved survival and the fact that mortality rates are
eadily measured in many clinical trials. Investigators have also
sed the avoidance of adverse events, such as ischemia-driven
epeat revascularization procedures (12), as effectiveness mea-
ures in CE studies; this approach appears most acceptable
hen the adverse events are associated with measurable dec-
ements in quality of life.
Some desirable interventions may not alter life expectancy
ut still offer value through reduction or avoidance of
ymptoms and improvement in quality of life, and others
ay significantly alter both the quantity and quality of life.
t is here that cost-utility analyses are recommended, with
ALYs serving as the preferred measure of effectiveness
11). Authorities favor the use of QALYs in CE studies
ecause, at least in theory, they can be measured across a
ide variety of health conditions. To calculate QALYs, one
ust measure utility weights, which reflect an individual’s
reference for a given health state on a scale ranging from
.0 (perfect health) to 0 (death) (13). A person’s (or
opulation’s average) utility may change over time and
hrough the course of an illness. QALYs are calculated as
tility multiplied by the length of time (in years) spent in
he health state corresponding with that utility, summed
ver time (Fig. 2).
The chief drawback to using QALYs for CE analysis lies
n the methods available for measuring utility. Gold-
tandard methods of directly eliciting utilities from patients
re strongly grounded in economic theory but difficult and
ime-consuming to apply in practice (14,15). For this
eason, investigators more often use indirect methods, in
hich study participants complete generic health state
lassification surveys (e.g., the EuroQol [16] or the Medical
utcomes Study Short-Form 36 [17]) that, in turn, have
reviously estimated utilities from reference populations for
ach health state defined by the survey (18,19). Due to the
ntricacies of utility assessment and conflicting guidance on
he topic, CE studies vary widely in their approach to
uality-of-life adjustment (20), and all too often the data
eeded for proper quality adjustment simply are not avail-
ble. We believe that the widespread availability of vali-
ated, multilingual instruments for assessment of popula-
ion utilities is an important recent advance that should lead
o increasing consistency and validity in health economic
tudies. wypes of Health Economic Studies
eaders will encounter 3 basic kinds of health economic
tudies, each with its own distinct strengths and limitations
Table 1). Trial-based studies (21,22) generally benefit from
areful and accurate data collection; from randomization,
hich minimizes bias and confounding; and from the
igorous adjudication of end points. However, important
spects of clinical trials may differ from the “real world” in
erms of patient selection and recruitment, clinical manage-
ent, or other factors that are important to economic
utcomes. Perhaps more importantly, clinical trials are often
imited by finite (and potentially short) time horizons and
nequal follow-up duration within groups. If the trial
uration is not sufficiently long to capture all of the
ertinent clinical and economic ramifications of the strate-
ies under study, then the estimation of CE may be biased
see the following text). Finally, pure trial-based analyses
end not to incorporate data from external sources, exposing
he results to potentially greater uncertainty than if evidence
rom other trials was considered.
Some economic studies derive entirely from disease-
imulation models (23). Common approaches in the med-
cal literature include Markov models (24) and discrete
vent simulation (25). Models are mathematical structures
hat represent the key aspects of the strategies under study,
nd can incorporate data from a wide variety of sources as
nputs. Models can estimate likely CE outcomes when
linical trials are not feasible, or not yet complete. In
ddition, model-based analyses can incorporate multiple
ompeting strategies, which are generally impractical to
xamine in a clinical trial setting. However, models gener-
lly require simplifying assumptions, and ultimately reflect
he accuracy of the source data on which they are built—
ood or poor. Finally, models can incorporate the results of
ystematic overviews of therapeutic efficacy (i.e., meta-
nalyses), thus overcoming limitations introduced by over-
eliance on the results of any single trial. When conducted
Figure 2 Quality-Adjusted Life Expectancy
To calculate quality-adjusted life expectancy, the time spent in a particular
health state (typically measured in years) is multiplied by the utility weight
(possible range of 0 to 1) for that health state, and these products are then
summed over time. Quality-adjusted life expectancy is thus represented by the
area under the hypothetical “curve” in this figure.ell, modeling studies make their assumptions transparent,
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Interpreting CE Studies December 16/23, 2008:2119–26est the impact of key assumptions, and, in so doing, may
dentify key areas of uncertainty on which future research
hould focus.
Increasingly, economic studies incorporating elements of
oth trial- and model-based methodologies have been reported
8,26). These hybrid studies can address the limitations of
rial-based analysis—in particular, the issue of truncated
ollow-up—by extending the results of the study through time,
enerating a range of plausible projections of longer-term
utcomes. While those projections are potentially subject to
ome of the same criticisms as purely model-based studies, the
ybrid approach can take advantage of the carefully collected
n-trial data to inform the modeling effort.
ey Principles in the Interpretation of CE Studies
nalytic perspective. One of the most important consid-
rations in interpreting CE research is the analytic perspec-
ive of the study. Most health systems are structured such
hat multiple parties are involved in the delivery, payment,
nd receipt of care. Each stakeholder (or group of stake-
olders), following their own incentives (e.g., to maximize
ealth, maximize revenue, or minimize expenditure), may,
hus, have very different views on what represents optimal
olicy for a particular intervention.
Table 2 illustrates the importance of perspective by
onsidering differing possible views on the usage of drug-
ypes of Health Care Economic Studies
Table 1 Types of Health Care Economic Studies
Definition
Trial-based Economic analysis performed
alongside clinical trial
● Precise measur
during trial and
● Randomization
Model-based Analytic structure developed using best
available evidence
● Predict likely ou
feasible
● Can incorporate
sources
● Can consider st
directly tested i
● Identify key are
“Hybrid” “In-trial” results extrapolated using
modeling techniques
● Trial data inform
● Adjust time hor
comparison
VID  Antiarrhythmics Versus Implantable Defibrillators; ICD  implantable cardioverter-defibrill
n Heart Failure Trial.
heoretical Impact of Alternative Perspectives on Cost-Effectivene
Table 2 Theoretical Impact of Alternative Perspectives on Cost
Perspective Objective
Patient Maximize personal health benefits
Hospital Maximize margin (revenue minus costs) for each epi
CMS/insurer Maintain health of beneficiaries with smallest possib
growth in cost
Society/health care
system
Maximize societal health benefits within constraint o
spending limitMS  bare-metal stent(s); CABG  coronary artery bypass grafting; CMS  Centers for Medicare & Medluting stents (DES) for patients with coronary artery
isease undergoing percutaneous coronary intervention. In
his hypothetical example, based on the initial reimburse-
ent policy for DES after their approval, the potentially
isparate incentives, obligations, and constraints of the
arious parties would lead—at least in theory—to different
references for one strategy versus another.
The standard recommendation for CE studies in medi-
ine is to use the most inclusive perspective possible, so as to
ncorporate the potential benefits, harms, and costs for all
arties involved. This defines the societal (or health system)
erspective, which flows from the desire for CE studies to
nform policy making at the broadest levels. Seen in this
ight, CE analyses are less concerned with individual win-
ers and losers of a particular strategy (e.g., surgeons vs.
ardiologists or hospitals vs. insurers), but rather with the
ore expansive aim of understanding the global balance
etween societal costs and societal benefits. Some have
rgued, however, that this approach is incomplete, and that
fully transparent accounting of CE should demonstrate
xplicitly the effect on each of the individual stakeholders.
his is likely one important reason that traditional CE
nalyses taking the societal perspective have not been more
idely used in policymaking.
ncremental comparisons. CE ratios are often reported as
incremental cost effectiveness ratios” (“iCERs” or “ICERs”),
ages Disadvantages
Examples From
ICD Literature
of costs and benefits
the same population
● Trial conditions may differ
from “real life”
MADIT (21)
AVID (22)
izes bias ● Limited time horizon
s when trials not
s from multiple
s that have not been
-to-head trials
● Require simplifying
assumptions
● Key model inputs may be
flawed or unknown
Sanders et al. (23)
ncertainty
del
r more “fair”
● Modeling portion has
same limitations as pure
model-based study
MADIT II (8)
SCD-HeFT (26)
DIT  Multicenter Automatic Defibrillator Implantation Trial; SCD-HeFT  Sudden Cardiac Death
DES
ctiveness of DES
Preference for DES
● DES for every lesion (assuming the patient has health insurance
and out-of-pocket expenses are minimal)
f care ● DES  BMS for discrete lesions that can be treated with 1 stent
(incremental reimbursement covers cost of 1.5 DES)
● Avoid DES for multivessel disease (especially vs. CABG)
● DES reasonable for patients currently receiving CABG
ll ● DES for patients where the expected clinical benefits are worth
the additional costAdvant
ement
within
minim
tcome
input
rategie
n head
as of u
s mo
izon foss of
-Effe
sode o
le
f overaicaid Services; DES  drug-eluting stent(s).
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December 16/23, 2008:2119–26 Interpreting CE Studiesith the “i” emphasizing the notion that CE is not an
nherent property of any one medical technology. Rather,
E can only be estimated by the direct comparison of one
linical strategy with another. An important tenet in the
alculation of “iCERs,” dictated by the economic theory
nderlying health economics research, is that each relevant
trategy should be compared with the next best alternative,
ased on the economic concept of “opportunity costs” (11).
Failure to make incremental comparisons with each
elevant strategy can lead to distortions in the calculation of
E ratios and potentially erroneous conclusions. This is
xemplified by the CE analysis of the COMPANION
Comparison of Medical Therapy, Pacing, and Defibrilla-
ion in Heart Failure) trial (27)—a 3-armed randomized
rial that compared medical therapy with cardiac resynchro-
ization pacemakers (CRT-Ps) or defibrillators (CRT-Ds)
n heart failure patients. As shown in Figure 3A, the
nalysts made separate comparisons of the CE of CRT-Ps
nd CRT-Ds with the “optimal medical therapy” control
roup. Both of these CE ratios appeared favorable. An
ditorialist, however, pointed out the omission of a com-
arison the trial was not designed specifically to address, but
hat was nonetheless of interest: CRT-Ps versus CRT-Ds
28). The significantly greater iCER for CRT-Ds when
ompared with CRT-Ps (Fig. 3B) raises important ques-
ions about the incremental value of the more expensive
echnology, and suggests that, under certain budgetary
onditions (i.e., below certain CE thresholds), the modestly
ess effective strategy of CRT-P might actually be preferred.
ime horizon. CE studies can be exquisitely sensitive to
he time horizon of analysis. Ideally, the time horizon of a
E study should cover the entire period over which the
nterventions may have an effect on either clinical or
conomic outcomes. As noted previously, this is a potential
eakness of purely trial-based analyses, particularly if a
trategy under study involves primarily up-front expendi-
ure, but provides clinical benefits that extend beyond the
uration of the trial—a common scenario for many preventive
trategies. In such cases, the incremental cost comparisons for
he trial may be roughly accurate, but the cumulative incre-
ental benefits may be significantly underestimated (because
uch of the benefit occurs beyond the time frame observed
uring the trial), resulting in artificially high CE ratios.
The CE studies from 2 recent implantable cardioverter-
efibrillator trials demonstrate these concepts. For both the
ADIT (Multicenter Automatic Defibrillator Implanta-
ion Trial) II and SCD-HeFT (Sudden Cardiac Death in
eart Failure Trial) studies, the up-front expenditures of
evice implantation coupled with the moderate length (3 to
years) of the trials translated into fairly high CE ratios
sing empirical in-trial data ($127,000 to $235,000 per
ife-year gained). To address this issue, both groups of
nvestigators also calculated CE ratios based on longer-term
rojections of survival and costs of their study cohorts, and
ound that the resulting CE ratios decreased to$60,000 to l80,000 per life year gained at 12 years (8,26), and
$40,000 per life-year gained in a lifetime model (26).
It is also possible for studies with limited time horizons to
nderestimate CE ratios, leading to an overly optimistic
iew of CE. This outcome might occur if a therapy requires
ontinuing long-term expense with diminishing clinical
eturns over time. For example, analysis from the CURE
Clopidogrel in Unstable angina to prevent Recurrent
vents) trial (29) found that the addition of clopidogrel to
aily aspirin for up to 1 year after an acute coronary
yndrome was highly cost-effective, with a CE ratio of
$10,000 per life year. In contrast, a separate modeling
tudy (30) explored the implications of longer-term therapy
or the same indication, and found that by 3 to 5 years,
ontinued clopidogrel treatment resulted in highly unfavor-
ble CE ratios because incremental benefit changed little
ver time, while incremental costs increased substantially,
Figure 3 Absolute Versus Incremental CE
The incremental costs (y-axis) and effectiveness (x-axis, in quality-adjusted life
years [QALYs]) for the 2 experimental arms of the COMPANION (Comparison of
Medical Therapy, Pacing, and Defibrillation in Heart Failure) trial are plotted
versus the control group of optimal medical therapy (27). In A, the reported
separate cost-effectiveness (CE) ratios for cardiac resychronization therapy
pacemakers (CRT-Ps) and cardiac resynchronization therapy defibrillators (CRT-
Ds) versus the control group both appear to be attractive from a U.S. perspec-
tive. The CE theory, however, dictates that each alternative is compared to the
next best. When this is done, as shown in B (28), the incremental CE ratio for
CRT-D versus CRT-P appears much larger.argely due to the continued cost of the drug itself.
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Interpreting CE Studies December 16/23, 2008:2119–26There is no single time horizon applicable to all CE
tudies. We believe that, for interventions that affect mor-
ality, the most appropriate time frame for analysis should
e the patient’s lifetime. While a lifetime perspective creates
nalytic challenges for investigators, including the potential
eed for highly uncertain extrapolations, it ensures that all
mportant long-term costs and benefits are considered. For
nterventions where all (or at least most) expenditures and
enefits occur in the near-term, fairly short time horizons may
e appropriate. One recent example of such an analysis is the
ase of DES versus bare-metal stents for patients undergoing
ercutaneous coronary intervention. In this case, both the
enefits and incremental costs of DES largely accrue during
he first year of follow-up (when restenosis generally occurs)
nd a 1-year, trial-based time horizon was reasonable (12,31).
ore recently, however, studies suggesting increased very late
tent thrombosis with DES have raised questions about the
alidity of such a short-term analytic perspective (32).
ncertainty. All empirical comparisons carry some amount
f uncertainty. In clinical studies, we generally describe this
ncertainty with familiar measures such as confidence in-
ervals, p values, and power. Unique features of economic
ata and CE studies require additional methods for mea-
uring and expressing uncertainty.
Particularly in the context of modeling, CE studies may
nclude many individual parameters that are poorly defined
r even completely unknown, thus requiring the analyst to
ake explicit assumptions about their values. The impact of
ssumed or uncertain individual parameters on the overall
esults of health economic studies must be systematically
valuated—a process known as uncertainty or sensitivity
nalysis (33). In a sensitivity analysis, model results are
ecalculated as important model parameters are varied across
plausible range of values. Sensitivity analyses not only
oint out which parameters do or do not significantly
nfluence overall results, but can also be used to estimate
hreshold values above or below which one strategy becomes
referred over another.
The greater the number of uncertain parameters in a
tudy, the more cumbersome sensitivity analysis becomes to
onduct and report. Moreover, sensitivity analyses of single
arameters also fail to communicate the overall uncertainty
f a modeled result. To address these problems, sophisti-
ated methods, such as probabilistic sensitivity analysis (also
nown as second-order Monte Carlo simulation), have been
eveloped that allow investigators to simultaneously vary
ny number of model inputs at once and thereby assess the
rue impact of the joint uncertainty in each parameter on a
odel’s overall findings (34,35). These techniques help to
stablish the confidence in a model’s conclusions by report-
ng the proportion of iterations that favor one strategy over
nother.
For trial-based analyses, specialized methods are also
equired to express the uncertainty around point estimates
or CE ratios, since neither the calculation nor interpreta-
ion of confidence intervals for CE ratios are straightfor- aard. Bootstrap resampling has emerged as one particularly
seful technique for handling this type of uncertainty
36,37). The bootstrap method involves creating a “dummy”
ataset by resampling with replacement (i.e., randomly
electing 1 patient at a time) from the original dataset and
epeating this random patient selection until the dummy
ataset reaches the same size as the original. The CE ratio
s then recalculated from the dummy dataset, and the entire
rocess is repeated many (e.g., 1,000) times. The average
E ratio, over many bootstrap iterations, should approxi-
ate the point estimate from the trial data, but when the
esult of each iteration is plotted on the CE plane, the
esults appear as a “cloud” of possible outcomes (Fig. 4),
eflecting the variability within the original study sample.
Once the bootstrap resampling calculations are com-
leted, the distribution of the various points in the “cloud”
an be analyzed in several instructive ways. First, confidence
ntervals for incremental costs, incremental effectiveness,
nd the joint distribution of the 2 can be generated.
urthermore, the proportion of points falling in the differ-
nt quadrants of the CE plane can be measured. Finally, the
roportion of incremental CE ratios falling above or below
ny hypothetical threshold can be reported.
Since the “optimal” threshold for CE ratios has never
een agreed upon, and would vary from place to place
nyway, a currently favored approach to visualize the infor-
ation obtained from bootstrap resampling of study results
s the construction of CE acceptability curves (38). In these
raphs (Fig. 5) (39), the probability that the intervention
nder investigation would be economically acceptable given
specific CE threshold (i.e., societal willingness to pay) is
lotted on the y-axis over a wide range of possible thresh-
lds, spread along the x-axis. CE acceptability curves
rovide readers with a rapid and understandable summary of
he uncertainty in a study’s CE point estimate, the thresh-
lds where 1 strategy becomes favored over others, and the
onfidence that specific thresholds of interest have or have
ot been met.
imitations of CE Research
E research is meant to be a source of unbiased information
or medical decision making and policy setting, for use in broad
pplications such as the development of clinical guidelines or
eimbursement policy. At their best, CE studies provide
nsight into the tradeoffs and consequences of certain choices
hat would not be apparent through assessment of clinical
utcomes alone. In general, however, the information obtained
rom CE studies is not well suited to clinical decision making
t the individual patient level. Nor is CE data sufficient, by
tself, for making complex resource allocation decisions, as
ealth economic studies cannot on their own incorporate all of
he values—such as equity, feasibility, or overall budgetary
mpact—that may be important. Total budget impact tends
o be particularly important for technologies where the
bsolute cost of adoption—whether due to a high per-patient
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December 16/23, 2008:2119–26 Interpreting CE Studiesmplementation cost or due to a large number of affected
ndividuals—is substantial.
Additional barriers have prevented the more explicit use
f CE data in the development of coverage and reimburse-
ent policy. These include political obstacles, for example,
he U.S. Medicare program has no statutory mandate to
Figure 4 Results of Bootstrap Resampling in a Trial-Based CE S
The joint distribution of projected lifetime differences in costs (y-axis) and life-expe
Events) trial population were recalculated over 5,000 replications of the study dat
plane. Each point in the scatterplot represents 1 bootstrap iteration. Data used,
Figure 5 CE Acceptability Curve
In this example, the likelihood that use of an embolic protection device during
percutaneous coronary intervention of a vein graft (vs. no distal protection) is
cost-effective is shown graphically across a range of theoretical cost-effective-
ness (CE) thresholds. For each CE threshold (increasing from left to right) on
the x-axis, the proportion of bootstrap iterations having a CE ratio at or below
that threshold is plotted on the y-axis. As indicated by the arrow, 97.3% of the
bootstrapped CE ratios were $40,000 per year of life gained. Reprinted, with
permission, from Cohen et al. (39).xamine CE and has resisted attempts to change this (40).
n addition, there are often valid concerns about the
ccuracy and transparency of CE data (41), and even the
est studies remain subject to limitations. Finally, it is
ncreasingly apparent that universal adoption of all new
edical technologies deemed “cost-effective” by conven-
ional criteria may have problematic budgetary conse-
uences for important stakeholders or for health systems in
eneral. For this reason, regulators outside the U.S. are
ncreasingly requiring budget impact analyses along with
E studies when assessing new therapies (42). Though the
rocesses differ, it is also clear that national coverage
ecisions undertaken by Medicare involve more careful
crutiny of clinical effectiveness when the financial stakes of
he decision are large.
Despite these limitations we believe CE analysis will
ontinue to grow in importance. As scientific and clinical
aboratories develop new technologies to benefit our pa-
ients, both the need for investigators capable of conducting
conomic assessments and the need for clinicians and
olicymakers to understand and critically appraise CE
iterature will grow as well.
eprint requests and correspondence: Dr. David. J. Cohen,
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